Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease

doi:10.3748/wjg.v23.i15.2771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16847)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-5) series.

Item

Count

PDF

1135

WORD

350

HTML

9185

Figures (1-10)

245

Tables (1-5)

186

Sum=11101

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

603

Download

1223

Sum=1826

Publishing Process of This Article

Item

Count

Browse

1480

Download

2440

Sum=3920

Apr 21, 2017 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (52)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Apr 21, 2017; 23(15): 2771-2784
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2771

Full Size Figure Download Figure

Figure 7 Receiver operating characteristic curves for indoleacetic acid, gluconic acid, 2-methylguanosine, cAMP, indoxylsulfuric acid, and acetyl-DL-leucine in the non-alcoholic steatohepatitis and control groups. NASH: Non-alcoholic steatohepatitis.

Citation: Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(15): 2771-2784
URL: https://www.wjgnet.com/1007-9327/full/v23/i15/2771.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i15.2771